AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12553384
Drug: Ropivacaine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 150 mg diluted in 60 mL NaCl 0.9%
Trial: 12553384
Drug: Ropivacaine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 150 mg diluted in 30 mL NaCl 0.9%
Trial: 12553384
Drug: Ropivacaine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 150 mg diluted in 40 mL NaCl 0.9%
Trial: 1491390
Drug: Chloroquine therapy
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine therapy
Trial: 31770012
Drug: Control (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (before inhalation, T1)
Trial: 27058481
Drug: Cognitive behavior-therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior-therapy anxiety-management (work-anxiety coping group, WAG)
Trial: 25233569
Drug: Pressure and
RxNorm normalized name: Blood Pressure and Pulse Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressure and topical anesthetic (20% benzocaine)
Trial: 25233569
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no concurrent stimulation)
Trial: 22234244
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) 1.25 mg and intravitreal triamcinolone acetonide (IVT) 2 mg
Trial: 15229206
Drug: Drospirenone oral
RxNorm normalized name: drospirenone Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drospirenone oral contraceptive (OC)
Trial: 9236408
Drug: Thrombomodulin gene
RxNorm normalized name: thymomodulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombomodulin gene mutations (GG‐9/‐10AT, G‐33A, C‐133A)
Trial: 1338525
Drug: Captopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (4 mg/l mixed into the cardioplegic solution)
Trial: 3315268
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline (mean 11.2 mg/kg per day)
Trial: 3315268
Drug: Sustained-release terbutaline
RxNorm normalized name: terbutaline Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release terbutaline (mean 0.25 mg/kg per day)
Trial: 27282133
Drug: Cinnamaldehyde (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamaldehyde (20 mg)
Trial: 28957728
Drug: Nicotine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (4 mg)
Trial: 27282133
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cinnamaldehyde and nicotine
Trial: 24419925
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg and Tadalafil 5 mg
Trial: 19083404
Drug: Purple passion
RxNorm normalized name: Purple passionflower
DrugBank: Passiflora incarnata flower (DB13974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purple passion fruit peel extract (150 mg/d)
Trial: 10518002
Drug: Plasma homocysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma homocysteine (HC) below 7.5 micromol/l
Trial: 10518002
Drug: Plasma vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma vitamin B12 (B12) above 300 pmol/l
Trial: 1646066
Drug: Prior locoregional
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior locoregional radiation therapy
Trial: 30450601
Drug: Control (buffer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (buffer solution)
Trial: 21291031
Drug: Sublingual ketorolac
RxNorm normalized name: ketorolac Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual ketorolac (30 mg/1 mL) and mepivacaine paracervical block
Trial: 21291031
Drug: Mepivacaine-only paracervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine-only paracervical injection (standard group)
Trial: 10023614
Drug: Intensive outpatient
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive outpatient or short-term residential treatment
Trial: 26799632
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg BI 135585 (single dose)
Trial: 26799632
Drug: 5-200 mg
RxNorm normalized name: hydrocodone
DrugBank: Hydrocodone (DB00956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-200 mg BI 135585 (multiple doses)
Trial: 22722509
Drug: Agomelatine (AGO)
DrugBank: Agomelatine (DB06594)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Agomelatine (AGO) 25-50 mg/d
Trial: 22722509
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR (VLX) 75-150 mg/d
Trial: 17598865
Drug: Twice-weekly PUVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly PUVA
Trial: 17598865
Drug: Thrice-weekly PUVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly PUVA
Trial: 12236845
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated beads (1 x 200 mg)
Trial: 12236845
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated mini-tablets (4 x 50 mg)
Trial: 12236845
Drug: Buffered tablet
RxNorm normalized name: CVS Aspirin 325mg Buffered Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered tablet (2 x 100 mg)
Trial: 11341606
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg bd for five days presurgery
Trial: 7488278
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg cM-T412
Trial: 2302375
Drug: Midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam and fentanyl combination
Trial: 6326562
Drug: Guar gum
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum (15 g/day)
Trial: 7435246
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or no medication
Trial: 26298832
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of vaporized cannabis (22 mg THC)
Trial: 26298832
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of vaporized cannabis (5.5 mg THC)
Trial: 12618744
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) as initial long-term control therapy
Trial: 11112027
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (tacrolimus/corticosteroids)
Trial: 11112027
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (tacrolimus/corticosteroids/azathioprine)
Trial: 8323890
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg plain bupivacaine (isobaric group)
Trial: 8323890
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg hyperbaric bupivacaine (hyperbaric group)
Trial: 3737634
Drug: Phenylpropanolamine (PPA)
DrugBank: Phenylpropanolamine (DB00397)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine (PPA) 25 mg
Trial: 3737634
Drug: Phenylpropanolamine (PPA)
DrugBank: Phenylpropanolamine (DB00397)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine (PPA) 75 mg
Trial: 3737634
Drug: Mazindol (MAZ)
RxNorm normalized name: Mazindol
DrugBank: Mazindol (DB00579)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mazindol (MAZ) 0.5 mg
Trial: 3737634
Drug: Mazindol (MAZ)
RxNorm normalized name: Mazindol
DrugBank: Mazindol (DB00579)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mazindol (MAZ) 2.0 mg
Trial: 3737634
Drug: D-amphetamine (AMP)
RxNorm normalized name: amphetamine / dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-amphetamine (AMP) 10 mg
Trial: 29388417
Drug: Tooth-borne distraction
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth-borne distraction osteogenesis (DO); activated twice daily by a total amount of 0.5 mm per day for 3 weeks after a 7-day latency period.
Trial: 20675956
Drug: Angiotensin II-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin II-receptor blockers (ARBs)
Trial: 18728281
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors or ARBs
Trial: 18436085
Drug: Individualized dietary
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized dietary counseling with regular follow-up (aimed at achieving an intake of 0.8 to 1.0 g/kg of protein and greater than 125 kJ/kg of energy)
Trial: 17283863
Drug: Azelnidipine 8‐16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelnidipine 8‐16 mg/day
Trial: 10805607
Drug: EHR (Progynova
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EHR (Progynova TS, transdermal estradiol; n=19)
Trial: 8793308
Drug: Residential relapse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residential relapse prevention/health education treatment
Trial: 1451289
Drug: Topical fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fish oil (FO) applied daily for 6 hours under an occlusive dressing for 4 weeks
Trial: 1451289
Drug: Liquid paraffin
RxNorm normalized name: Liquid paraffin
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid paraffin (LP) applied daily for 6 hours under an occlusive dressing for 4 weeks
Trial: 1451289
Drug: Topical fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fish oil (FO)
Trial: 26907502
Drug: Wii-based Movement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wii-based Movement Therapy (WMT)
Trial: 26907502
Drug: modified Constraint‐induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified Constraint‐induced Movement Therapy (mCIMT)
Trial: 12370217
Drug: ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe (10 mg/d)
Trial: 19965915
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (ezetimibe + simvastatin)
Trial: 18340009
Drug: 20 mg/d
RxNorm normalized name: Valtoco, 20 mg/dose nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/d fluvastatin
Trial: 16007894
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam RT as a postoperative adjunct
Trial: 12429759
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy with three treatments of 2000 pulses each and a positive energy flux density (ED+) of 0.07 to 0.09 mJ/mm²
Trial: 12429759
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy and Placebo therapy
Trial: 7826828
Drug: Fluvastatin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 2.5 mg day-1
Trial: 7826828
Drug: Fluvastatin 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 5 mg day-1
Trial: 7826828
Drug: Fluvastatin 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 10 mg day-1
Trial: 7826828
Drug: Fluvastatin 20
RxNorm normalized name: fluvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 20 mg day-1
Trial: 2901122
Drug: Acebutolol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (400 mg once daily)
Trial: 23827820
Drug: Jitai tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jitai tablets (JTT)
Trial: 20629478
Drug: Lactose doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose doses of 0-2 grams (lactose-reduced solution/milk)
Trial: 20629478
Drug: Varying lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varying lactose doses
Trial: 20629478
Drug: Other agents
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other agents (not specified)
Trial: 20629478
Drug: Lactose doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose doses of 12-15 grams
Trial: 20629478
Drug: Lactose doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose doses above 12 grams
Trial: 3945045
Drug: Ferrous sulphate
RxNorm normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulphate (80 mg Fe++ three times daily) for 6 weeks
Trial: 6692967
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no iron therapy)
Trial: 30215785
Drug: 21‐mg nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21‐mg nicotine patch for 24 weeks with behavior counseling
Trial: 30215785
Drug: 21‐mg nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21‐mg nicotine patch for 8 weeks with behavior counseling
Trial: 30215785
Drug: 21‐mg nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21‐mg nicotine patch for 52 weeks with behavior counseling
Trial: 20027108
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg intravenous rolofylline, 4-hour infusions once daily for 4 consecutive days
Trial: 20027108
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of midazolam 7.5 mg
Trial: 20027108
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg intravenous rolofylline
Trial: 10586391
Drug: Theophylline (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (IV infusion)
Trial: 10586391
Drug: Amikacin (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin (IV infusion)
Trial: 23879234
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MMF) 0.1% ointment for 12 weeks
Trial: 21878580
Drug: Se+highI (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Se+highI (100 μg selenium + >50 mg iodine as iodate/day for 8 weeks)
Trial: 21878580
Drug: highI (>50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: highI (>50 mg iodine as iodate/day for 8 weeks)
Trial: 21878580
Drug: Se+lowI (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Se+lowI (80 μg iodine as iodate/day + selenium)
Trial: 21878580
Drug: lowI (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lowI (80 μg iodine as iodate/day without selenium)
Trial: 18645345
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion (0.5-3 microg/kg/min)
Trial: 7528949
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin (Trasylol)
Trial: 8655886
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (200 micrograms once daily)
Trial: 3966746
Drug: Delay in
RxNorm normalized name: Delayed Release Oral Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delay in initiation of treatment
Trial: 30917302
Drug: 0.15% benzydamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% benzydamine hydrochloride (Tantum Verde®) mouthwash solution
Trial: 23241227
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Ranibizumab + PDT)
Trial: 21496998
Drug: Hilotherm cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hilotherm cooling therapy
Trial: 19085267
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sedating H1 antihistamine and non‐sedating H1 antihistamine (Group A)
Trial: 19085267
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of H1 antihistamine and H2 antihistamine (Group B)
Trial: 19085267
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of H1 antihistamine and leukotriene receptor antagonist (LRA) (Group C)
Trial: 19085267
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo medication (Group D)
Trial: 14630840
Drug: Oral alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alendronate at a dose of 10 mg/day for six months
Trial: 10832506
Drug: Sahaja Yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sahaja Yoga meditation twice daily for 6 months
Trial: 2951793
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fenoterol and ipratropium bromide (Duovent)
Trial: 24894416
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (non-SSRIs)
Trial: 1460149
Drug: Various forms
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various forms of treatment for depression
Trial: 6376207
Drug: Chlorthalidone 25
RxNorm normalized name: chlorthalidone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 25 mg/triamterene 50 mg
Trial: 10395628
Drug: Live-culture yogurt
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live-culture yogurt (200 g/d for 1 year)
Trial: 10395628
Drug: Pasteurized yogurt
RxNorm normalized name: Human fibrinogen concentrate, pasteurized
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasteurized yogurt (200 g/d for 1 year)
Trial: 2160356
Drug: Plasma parathyroid
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plasma parathyroid hormone
Trial: 2160356
Drug: Discriminant function
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discriminant function based on parathyroid hormone and alkaline phosphatase
Trial: 25369827
Drug: Probiotic (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic (5 × 10(9) CFUs; twice daily)
Trial: 22901562
Drug: Resveratrol (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (250 mg/d) along with oral hypoglycemic agents
Trial: 22901562
Drug: Oral hypoglycemic
RxNorm normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hypoglycemic agents only
Trial: 11328262
Drug: Aspirin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (400 mg b.d.)
Trial: 11328262
Drug: Aspirin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (400 mg b.d.) + Vitamin C (480 mg b.d.)
Trial: 9877109
Drug: Calcium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium infusion rate varied to produce a fall of at least 0.2 mmol/l in ionized calcium during hemodialysis.
Trial: 9877109
Drug: Calcium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium infusion rate maintained stable ionized calcium during hemodialysis.
Trial: 172181
Drug: Natural oestrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural oestrogen administration
Trial: 172181
Drug: Synthetic oestrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic oestrogen administration with oral contraception
Trial: 28664557
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy (O2)
Trial: 19168107
Drug: DNA vaccine
RxNorm normalized name: HTNV DNA vaccine
DrugBank: Hantaan virus DNA vaccine (DB17808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA vaccine (intramuscularly or intradermally)
Trial: 15285057
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of Iohexol 300
Trial: 15285057
Drug: 75 ml
RxNorm normalized name: ethanol 0.75 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 ml of Ioversol 320
Trial: 9630829
Drug: OPC‐31260 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC‐31260 (30 mg, orally)
Trial: 7946238
Drug: Regular use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular use of medication with family intervention
Trial: 29932590
Drug: Phase II
RxNorm normalized name: Coxiella burnetii phase II Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase II intervention (3 monthly classes, 60 minutes each, postpartum)
Trial: 20026575
Drug: Adjustment group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustment group intervention (six, 2-hour group treatment sessions)